MEREO BIOPHARMA GROUP PLC Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset of -GBP 2.69 thousand for the 12-month period ending 2019-12-31, per its 20-F filed 2020-06-15.
Discontinued › Notes › Income Taxes
ifrs-full:IncreaseDecreaseThroughLossOfControlOfSubsidiaryDeferredTaxLiabilityAsset · last filed 2020-06-15
| Period end | Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset 12 month |
|---|---|
| 2019-12-31 | -2.69K GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |